RNXT (RenovoRx Inc.) stock: $1.23, $59.4M market cap, $10.4M cash, $49.0M EV, $101.3M fully diluted market cap. Next expected readout: Jun-27. Lead program: Gemcitabine (Locally Advanced Pancreatic Cancer), Phase 3. Data from Fully Diluted's biotech stocks database.
What they do
We are a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ® , a novel, U.S. Food and Drug Administration (“FDA”)-cleared local drug-delivery device, targeting high unmet medical needs. Our mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of therapeutic agents.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Status note Intra-arterial gemcitabine delivered via RenovoCath (TAMP platform) in ongoing Phase III TIGeR-PaC trial for LAPC. Orphan Drug Designation for pancreatic cancer and bile duct cancer. New IIT in cholangiocarcinoma began Q2 2026.
Oxaliplatin (TAMP)
Stage not disclosed · ActiveModality: drug-device combination
Indications
Pancreatic cancer(Stage not disclosed)
Status note Oxaliplatin delivered via RenovoCath under TAMP platform; Orphan Drug Designation granted Q2 2026 for pancreatic cancer.
RenovoCath
Approved · ActiveModality: medical device
Indications
Vessel occlusion (device indication)(Approved)
Status note FDA-cleared for temporary vessel occlusion (arteriography, preoperative occlusion, chemotherapeutic drug infusion). Actively commercialized as standalone device.
Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.